Can tedizolid be used as primary therapy for gastric infections or acute cholecystitis in an adult patient without documented MRSA infection?

Tedizolid Should NOT Be Used for Gastric Infections or Cholecystitis

Tedizolid is FDA-approved exclusively for acute bacterial skin and skin structure infections (ABSSSI) and has no role in the treatment of intra-abdominal infections, including gastric infections or acute cholecystitis 1.

Why Tedizolid is Inappropriate for These Infections

Wrong Spectrum of Activity

The established guidelines for complicated intra-abdominal infections, including cholecystitis, require coverage against:

• Gram-negative aerobic/facultative organisms (primarily E. coli, Klebsiella, Proteus)
• Obligate anaerobes (Bacteroides fragilis group)
• Gram-positive streptococci 2

Tedizolid only covers gram-positive organisms and has no activity against the gram-negative and anaerobic pathogens that dominate biliary and gastric infections 1, 3, 4.

Guideline-Recommended Regimens

For mild-to-moderate community-acquired intra-abdominal infections (including cholecystitis), the 2010 IDSA/SIS guidelines recommend 2:

Single-agent options:

• Ticarcillin-clavulanate
• Cefoxitin
• Ertapenem
• Moxifloxacin
• Tigecycline

Combination regimens:

• Metronidazole PLUS (cefazolin, cefuroxime, ceftriaxone, cefotaxime, levofloxacin, or ciprofloxacin)

For high-severity infections, broader gram-negative coverage is required with carbapenems, piperacillin-tazobactam, or fluoroquinolones plus metronidazole 2.

When MRSA Coverage Might Be Needed

Even in the rare scenario where MRSA is documented in an intra-abdominal infection:

• Empiric MRSA coverage is NOT recommended for community-acquired intra-abdominal infections 2
• MRSA represents only 4% of isolates in these infections 2
• If MRSA is documented, vancomycin or linezolid would be added to a regimen that already covers gram-negatives and anaerobes—not used as monotherapy 2

Clinical Reality Check

Common pitfall: Clinicians sometimes inappropriately extrapolate tedizolid's excellent MRSA activity to other infection types. This is dangerous because:

1. Biliary infections are polymicrobial with predominantly gram-negative organisms
2. Using tedizolid alone would leave E. coli, Klebsiella, and Bacteroides completely untreated
3. This would result in treatment failure and potential progression to sepsis

Recent data confirms poor adherence to appropriate antibiotic selection for cholecystitis, with only 45% of patients receiving guideline-concordant therapy 5. Do not contribute to this problem by using tedizolid.

The Correct Approach

For acute cholecystitis without documented MRSA:

• Start with ceftriaxone 1g IV daily (covers biliary gram-negatives and streptococci)
• Add metronidazole 500mg IV q8h if severe disease or concern for anaerobes
• Adjust based on bile cultures if obtained 2, 6

For gastric perforation/infection:

• Use regimens covering gram-positives, gram-negatives, and anaerobes
• Examples: piperacillin-tazobactam or ceftriaxone + metronidazole 2

Only consider adding MRSA-active agents (vancomycin, linezolid—NOT tedizolid for prolonged therapy) if:

• MRSA is cultured from bile or blood
• Healthcare-associated infection with known MRSA colonization
• Patient fails initial appropriate therapy 2